Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasser:Hehlmann, Rüdiger [VerfasserIn]   i
 Saußele, Susanne [VerfasserIn]   i
 Fabarius, Alice [VerfasserIn]   i
 Kohlbrenner, Katharina Maria [VerfasserIn]   i
 Voskanyan, Astghik [VerfasserIn]   i
 Rinaldetti, Sébastien [VerfasserIn]   i
 Seifarth, Wolfgang [VerfasserIn]   i
 Spiess, Birgit [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
Titel:Assessment of imatinib as first-line treatment of chronic myeloid leukemia
Titelzusatz:10-year survival results of the randomized CML study IV and impact of non-CML determinants
Verf.angabe:R. Hehlmann, M. Lauseker, S. Saußele, M. Pfirrmann, S. Krause, H.J. Kolb, A. Neubauer, D.K. Hossfeld, C. Nerl, A. Gratwohl, G.M. Baerlocher, D. Heim, T.H. Brümmendorf, A. Fabarius, C. Haferlach, B. Schlegelberger, M.C. Müller, S. Jeromin, U. Proetel, K. Kohlbrenner, A. Voskanyan, S. Rinaldetti, W. Seifarth, B. Spieß, L. Balleisen, M.C. Goebeler, M. Hänel, A. Ho, J. Dengler, C. Falge, L. Kanz, S. Kremers, A. Burchert, M. Kneba, F. Stegelmann, C.A. Köhne, H.W. Lindemann, C.F. Waller, M. Pfreundschuh, K. Spiekermann, W.E. Berdel, L. Müller, M. Edinger, J. Mayer, D.W. Beelen, M. Bentz, H. Link, B. Hertenstein, R. Fuchs, M. Wernli, F. Schlegel, R. Schlag, M. de Wit, L. Trümper, H. Hebart, M. Hahn, J. Thomalla, C. Scheid, P. Schafhausen, W. Verbeek, M.J. Eckart, W. Gassmann, A. Pezzutto, M. Schenk, P. Brossart, T. Geer, S. Bildat, E. Schäfer, A. Hochhaus and J. Hasford for the SAKK and the German CML Study Group
Umfang:9 S.
Fussnoten:Advance online publication, 12 September 2017 ; Gesehen am 21.06.2018
Titel Quelle:Enthalten in: Leukemia
Jahr Quelle:2017
Band/Heft Quelle:31(2017), 11, S. 2398-2406
ISSN Quelle:1476-5551
Abstract:Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients’ and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival.
DOI:doi:10.1038/leu.2017.253
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Verlag: http://dx.doi.org/10.1038/leu.2017.253
 Verlag: http://www-nature-com/articles/leu2017253
 DOI: 10.1038/leu.2017.253
Datenträger:Online-Ressource
Sprache:eng
K10plus-PPN:1576727033
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68263873   QR-Code
zum Seitenanfang